美晶片軟件公司Cadence(CDNS.US)及Synopsys(SNPS.US)稱將恢復對中國客戶供應
綜合外媒報道,美國晶片軟件公司Cadence Design Systems(CDNS.US)及Synopsys(SNPS.US)分別表示,美國已移除對中國的晶片設計軟件出口管制,正恢復受影響客戶接入軟件。《彭博》報道,德國西門子早前聲明表示,已獲美國商務部通知,其在中國開展業務不再需要申請許可。
美國5月實施有關出口管制,回應對中國對稀土出口審批。根據上周最終達成的貿易協議,美國承諾允許向中國出口晶片設計軟體、乙烷和噴射引擎,條件是北京兌現其加速審批關鍵礦物出口的承諾。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.